| 000 | 01419 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250512022406.0 | ||
| 264 | 0 | _c19881130 | |
| 008 | 198811s 0 0 eng d | ||
| 022 | _a0340-6245 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGrimaudo, V | |
| 245 | 0 | 0 |
_aFibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination. _h[electronic resource] |
| 260 |
_bThrombosis and haemostasis _cJun 1988 |
||
| 300 |
_a388-91 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 |
_aCircadian Rhythm _xdrug effects |
| 650 | 0 | 4 |
_aDihydroergotamine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aFactor Xa |
| 650 | 0 | 4 |
_aFibrinolysis _xdrug effects |
| 650 | 0 | 4 |
_aHeparin _xpharmacology |
| 650 | 0 | 4 |
_aHeparin, Low-Molecular-Weight _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aSerine Proteinase Inhibitors |
| 700 | 1 | _aOmri, A | |
| 700 | 1 | _aKruithof, E K | |
| 700 | 1 | _aHauert, J | |
| 700 | 1 | _aBachmann, F | |
| 773 | 0 |
_tThrombosis and haemostasis _gvol. 59 _gno. 3 _gp. 388-91 |
|
| 999 |
_c2853210 _d2853210 |
||